Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate.

@article{Oms1994BiochemicalCA,
  title={Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate.},
  author={Philippe Oms and Nathalie Assie and F. Bruniquel and Annelies Degryse and G van Haverbeke and Andr{\'e} Delhon},
  journal={Pharmacology \& toxicology},
  year={1994},
  volume={77 6},
  pages={
          391-6
        }
}
  • P. OmsN. Assie A. Delhon
  • Published 1 September 1994
  • Biology, Medicine, Chemistry
  • Pharmacology & toxicology
View on PubMed
doi.org
5 Citations
Background Citations
2

5 Citations

Select 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors vary in their ability to reduce egg yolk cholesterol levels in laying hens through alteration of hepatic cholesterol biosynthesis and plasma VLDL composition.

Cholesterol per se may not be an obligatory component for yolk formation in chickens and, as such, may be amenable to further pharmacological manipulation.

Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study

It is proposed, for the first time, that dietary cholesterol significantly contributes to statin-related hepatotoxicity, providing valuable insight into the clinical use of statins.

The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human Risk

These approaches of mechanism-based risk assessment predicted that most of the adverse effects observed in animals would not be seen under conditions of human use and supported the successful introduction of one of the most important classes of human medicines.

Molecular mechanisms of toxicity of simvastatin, widely used cholesterol-lowering drug. A review

Details about statins including their adverse effects in humans and animals, the effects of simvastatin on various intracellular and mitochondrial processes, and molecular mechanisms underlying simvastsatin cytotoxicity are discussed.

Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.

Findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.